-
1.发明申请公开(公告)号：US20190382829A1
公开(公告)日：2019-12-19
申请号：US16227778
申请日：2018-12-20
申请人： Geron Corporation
IPC分类号： C12Q1/6813 , C12Q1/6883 , C12N15/113
摘要： The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
-
公开(公告)号：US20220325327A1
公开(公告)日：2022-10-13
申请号：US17533825
申请日：2021-11-23
申请人： Geron Corporation
IPC分类号： C12Q1/6813 , C12Q1/6883 , G16B30/00 , A61K48/00 , C12N15/113
摘要： The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
-
3.发明公开公开(公告)号：US20240318232A1
公开(公告)日：2024-09-26
申请号：US18491658
申请日：2023-10-20
申请人： Geron Corporation
IPC分类号： C12Q1/6813 , A61K48/00 , C12N15/113 , C12Q1/6883 , G16B30/00
CPC分类号： C12Q1/6813 , A61K48/00 , C12N15/1137 , C12Q1/6883 , G16B30/00 , C12Q2600/106 , C12Q2600/156
摘要： The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
-
公开(公告)号：US20210269861A1
公开(公告)日：2021-09-02
申请号：US17029815
申请日：2020-09-23
申请人： Geron Corporation
IPC分类号： C12Q1/6813 , C12Q1/6883 , G16B30/00 , A61K48/00 , C12N15/113
摘要： The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
-
5.发明申请Method for Eliciting an Immune Response to Human Telomerase Reverse Transcriptase 审中-公开引起人端粒酶逆转录酶免疫反应的方法公开(公告)号：US20150250863A1
公开(公告)日：2015-09-10
申请号：US14190021
申请日：2014-02-25
发明人： Thomas R. Cech , Joachim Lingner , Toru M. Nakamura , Karen B. Chapman , Gregg B. Morin , Calvin B. Harley , William H. Andrews
CPC分类号： A61K39/0011 , A01K2217/05 , A61K38/00 , A61K39/0005 , A61K39/39 , A61K48/00 , A61K2039/55505 , A61K2039/55511 , A61K2039/55516 , A61K2039/55544 , A61K2039/55566 , A61K2039/575 , C07K14/43504 , C07K16/40 , C07K2319/00 , C12N9/1241 , C12N9/1276 , C12N15/113 , C12N15/1137 , C12N2310/15 , C12N2310/315 , C12Q1/6895 , C12Q2600/156 , C12Q2600/158 , C12Y207/07049
摘要： The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
摘要翻译： 本发明提供了与人类端粒酶逆转录酶（hTRT），人端粒酶的催化蛋白质亚基相关的组合物和方法。 本发明的多核苷酸和多肽可用于人类疾病的诊断，预后和治疗，用于改变细胞和生物体的增殖能力，以及用于鉴定和筛选用于治疗诸如癌症的疾病的化合物和治疗。
-
公开(公告)号：US10196677B2
公开(公告)日：2019-02-05
申请号：US15445428
申请日：2017-02-28
申请人： Geron Corporation
IPC分类号： A61K48/00 , C07H21/04 , C12Q1/6813 , C12Q1/6883 , C12N15/113
摘要： The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
-
公开(公告)号：US20230114322A1
公开(公告)日：2023-04-13
申请号：US17752106
申请日：2022-05-24
申请人： Geron Corporation
IPC分类号： C12Q1/6813 , C12Q1/6883 , G16B30/00 , A61K48/00 , C12N15/113
摘要： The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
-
8.发明申请公开(公告)号：US20170298421A1
公开(公告)日：2017-10-19
申请号：US15445428
申请日：2017-02-28
申请人： Geron Corporation
IPC分类号： C12Q1/68 , C12N15/113
CPC分类号： C12Q1/6813 , C12N15/1137 , C12Q1/6883 , C12Q2600/106 , C12Q2600/156
摘要： The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
-
公开(公告)号：US09617583B2
公开(公告)日：2017-04-11
申请号：US14505366
申请日：2014-10-02
申请人： Geron Corporation
CPC分类号： C12Q1/6813 , C12N15/1137 , C12Q1/6883 , C12Q2600/106 , C12Q2600/156
摘要： The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
-
10.发明申请公开(公告)号：US20150152488A1
公开(公告)日：2015-06-04
申请号：US14505366
申请日：2014-10-02
申请人： Geron Corporation
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6813 , C12N15/1137 , C12Q1/6883 , C12Q2600/106 , C12Q2600/156
摘要： The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
摘要翻译： 本发明提供了在端粒酶抑制剂治疗开始之前通过测量患者适当细胞中端粒长度来测定癌症患者发生不良反应的敏感性的方法。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.029 秒)
